Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SPARTAN: Apalutamide delays second progression in nonmetastatic CRPC

Publish date:: October 18, 2019

Key clinical point: Apalutamide was associated with longer time to second progression in nonmetastatic, castration-resistant prostate cancer.

Major finding: Apalutamide was associated with a 45% reduction in risk of second progression.

Study details: An interim analysis of a phase 3, randomized trial in 1207 men with nonmetastatic, castration-resistant prostate cancer.

Disclosures: The SPARTAN trial was funded by Janssen. Dr. Smith disclosed an advisory role, research funding, and travel reimbursement for Janssen and others. Dr. Fizazi disclosed consulting for Janssen and others.

Citation:

Smith MR et al. ESMO 2019, Abstract 843O.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,